EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Who will benefit from vorasidenib? Review of data from the literature and open questions

Amélie Darlix iD, Matthias Preusser iD, Shawn L Hervey-Jumper, Helen A Shih, Emmanuel Mandonnet iD, Jennie W Taylor

Neuro-Oncology Practice · 06.01.2025 · 12 (Supplement_1) · i6-i18

DOI: 10.1093/nop/npae104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology Practice, online erschienen am 14.11.2024. Verfasst von Amélie Darlix und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical efficacy of isocitrate dehydrogenase (IDH) inhibitors in the treatment of patients with grade 2 IDH-mutant (mIDH) gliomas is a significant therapeutic advancement in neuro-oncology. It expands treatment options beyond traditional radiation therapy and cytotoxic chemotherapy, which may lead to significant long-term neurotoxic effects while extending patient survival. The INDIGO study demonstrated that vorasidenib, a pan-mIDH inhibitor, improved progression-free survival for patients with grade 2 mIDH gliomas following surgical resection or biopsy compared to placebo and was well tolerated. However, these encouraging results leave a wake of unanswered questions: Will higher-grade mIDH glioma patients benefit? When is the appropriate timing to start and stop treatment? Where does this new treatment option fit in with other treatment modalities? In this study, we review the limited data available to start addressing these questions, provide a framework of how to discuss these gaps with current patients, and highlight what is needed from the neuro-oncology community for more definitive answers.

Schlagwörter

Stichwörter der Autor:innen

IDH inhibitorsIDH-mutant gliomasivosidenibvorasidenib

Autor:innen und Institutionen

  • Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
  • Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM, Montpellier, France.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurosurgery, Lariboisière Hospital, AP-HP, Paris, France.

ORCID-Profile: Amélie Darlix, Matthias Preusser, Emmanuel Mandonnet

Zitieren

APA

Darlix, A., Preusser, M., Hervey-Jumper, S. L., Shih, H. A., Mandonnet, E., & Taylor, J. W. (2025). Who will benefit from vorasidenib? Review of data from the literature and open questions. Neuro-Oncology Practice, 12(Supplement_1), i6-i18. https://doi.org/10.1093/nop/npae104

Vancouver

Darlix A, Preusser M, Hervey-Jumper SL, Shih HA, Mandonnet E, Taylor JW. Who will benefit from vorasidenib? Review of data from the literature and open questions. Neuro-Oncology Practice. 2025;12(Supplement_1):i6-i18. doi:10.1093/nop/npae104

BibTeX
@article{Darlix2025,
  author = {Darlix, Amélie and Preusser, Matthias and Hervey-Jumper, Shawn L and Shih, Helen A and Mandonnet, Emmanuel and Taylor, Jennie W},
  title = {Who will benefit from vorasidenib? Review of data from the literature and open questions},
  journal = {Neuro-Oncology Practice},
  year = {2025},
  volume = {12},
  number = {Supplement_1},
  pages = {i6--i18},
  doi = {10.1093/nop/npae104}
}
Kostenlos starten →